XML 48 R17.htm IDEA: XBRL DOCUMENT
v3.22.2

Equity | 6 Months Ended
--- | ---
Jun. 30, 2022
Equity [Abstract] |
Equity | Share Repurchases In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 2.4 million shares of our common stock at a cost of approximately $500.0 million during the three and six months ended June 30, 2022. During the three and six months ended June 30, 2021, we repurchased and retired approximately 1.6 million and 3.8 million shares of our common stock at a cost of approximately $450.0 million and $1.1 billion, respectively. Approximately $2.3 billion remained available under our 2020 Share Repurchase Program as of June 30, 2022. Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:
(In millions) |  | Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Gains (Losses) on Net Investment Hedges, Net of Tax(1) |  | Unrealized gains (losses) on pension benefit obligation, Net of Tax |  | Currency Translation Adjustments |  | Total
Balance, December 31, 2021 |  | $ | (2.2) |  |  | $ | 53.8 |  |  | $ | 25.5 |  |  | $ | (44.8) |  |  | $ | (139.0) |  |  | $ | (106.7) |
Other comprehensive income (loss) before reclassifications |  | (19.1) |  |  | 129.5 |  |  | 12.6 |  |  | 2.7 |  |  | (94.9) |  |  | 30.8 |
Amounts reclassified from accumulated other comprehensive income (loss) |  | 1.1 |  |  | (56.4) |  |  | (38.1) |  |  | — |  |  | 58.9 |  |  | (34.5) |
Net current period other comprehensive income (loss) |  | (18.0) |  |  | 73.1 |  |  | (25.5) |  |  | 2.7 |  |  | (36.0) |  |  | (3.7) |
Balance, June 30, 2022 |  | $ | (20.2) |  |  | $ | 126.9 |  |  | $ | — |  |  | $ | (42.1) |  |  | $ | (175.0) |  |  | $ | (110.4) |
(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.
(In millions) |  | Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Gains (Losses) on Net Investment Hedges, Net of Tax |  | Unrealized gains (losses) on pension benefit obligation, Net of Tax |  | Currency Translation Adjustments |  | Total
Balance, December 31, 2020 |  | $ | 1.4 |  |  | $ | (179.0) |  |  | $ | (8.5) |  |  | $ | (66.3) |  |  | $ | (46.6) |  |  | $ | (299.0) |
Other comprehensive income (loss) before reclassifications |  | (2.0) |  |  | 90.2 |  |  | 20.2 |  |  | 2.4 |  |  | (32.6) |  |  | 78.2 |
Amounts reclassified from accumulated other comprehensive income (loss) |  | 0.7 |  |  | 48.4 |  |  | (0.1) |  |  | — |  |  | — |  |  | 49.0 |
Net current period other comprehensive income (loss) |  | (1.3) |  |  | 138.6 |  |  | 20.1 |  |  | 2.4 |  |  | (32.6) |  |  | 127.2 |
Balance, June 30, 2021 |  | $ | 0.1 |  |  | $ | (40.4) |  |  | $ | 11.6 |  |  | $ | (63.9) |  |  | $ | (79.2) |  |  | $ | (171.8) |
The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):
(In millions) | Income Statement Location |  | Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Gains (losses) on securities available for sale | Other (income) expense |  | $ | (0.8) |  |  | $ | (0.4) |  |  | $ | (1.4) |  |  | $ | (0.9) |
| Income tax benefit (expense) |  | 0.2 |  |  | 0.1 |  |  | 0.3 |  |  | 0.2 |
Gains (losses) on cash flow hedges | Revenue |  | 44.6 |  |  | (30.7) |  |  | 65.5 |  |  | (53.8) |
| Operating expense |  | (2.4) |  |  | 0.4 |  |  | (2.7) |  |  | — |
| Other (income) expense |  | (0.1) |  |  | (0.1) |  |  | (0.2) |  |  | 0.1 |
| Income tax benefit (expense) |  | (4.2) |  |  | 3.0 |  |  | (6.2) |  |  | 5.3 |
Gains (losses) on net investment hedges(1) | Other (income) expense |  | 39.2 |  |  | 0.1 |  |  | 38.1 |  |  | 0.1 |
Currency Translation Adjustments | Other (income) expense |  | (58.9) |  |  | — |  |  | (58.9) |  |  | — |
Total reclassifications, net of tax |  |  | $ | 17.6 |  |  | $ | (27.6) |  |  | $ | 34.5 |  |  | $ | (49.0) |
(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration